Neoplastic fever in patients with bone and soft tissue sarcoma
- PMID: 27900101
- PMCID: PMC5103890
- DOI: 10.3892/mco.2016.1027
Neoplastic fever in patients with bone and soft tissue sarcoma
Abstract
The development of fever is a common complication in the clinical course of cancer. If all other potential causes of fever are excluded, the possibility of neoplastic fever should be considered. The aim of the present study was to determine the incidence of neoplastic fever in patients with bone and soft tissue sarcomas. Between January 2009 and December 2014, 195 patients with bone and soft tissue sarcoma (111 men and 84 women; mean age, 55 years) were admitted to the Department of Orthopaedic Surgery of Mie University Graduate School of Medicine (Tsu, Japan). Episodes of fever were observed in 58 patients (30%), of whom 11 (5.5%) had neoplastic fever (mean maximum temperature, 38.9°C). The causes of neoplastic fever were as follows: Primary tumor (n=3), local recurrence (n=1), metastasis (n=5), and local recurrence with metastasis (n=2). Of the 11 patients, 9 were treated with naproxen and 8 exhibited a complete response, with their temperature normalizing to <37.3°C within 24 h. The 2 patients who were not treated with naproxen underwent surgical tumor resection, which resulted in prompt and complete lysis of the fever. In conclusion, neoplastic fever occurred in 5.5% of the 195 patients with bone and soft tissue sarcomas investigated herein. Naproxen may be effective for treating neoplastic fever in patients with bone and soft tissue sarcoma; however, radical tumor treatment may have to be considered to achieve permanent lysis of the fever.
Keywords: bone sarcoma; naproxen; neoplastic fever; soft-tissue sarcoma.
References
-
- Park S, Kang CI, Chung DR, Peck KR, Kim WS, Kim SJ. Clinical significance of non-neutropenic fever in the management of diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Comparison with febrile neutropenia and risk factor analysis. Cancer Res Treat. 2015;47:448–457. doi: 10.4143/crt.2014.034. - DOI - PMC - PubMed
-
- Bacci G, Ferrari S, Longhi A, Picci P, Mercuri M, Alvegard TA, Saeter G, Donati D, Manfrini M, Lari S, et al. High-dose ifosfamide in combination with high-dose methotrexate, adriamycin and cysplatin in the neoadjuvant treatment of extremity osteosarcoma: Preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother. 2002;14:198–206. doi: 10.1179/joc.2002.14.2.198. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources